BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26731754)

  • 21. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.
    Bots ML; Palmer MK; Dogan S; Plantinga Y; Raichlen JS; Evans GW; O'Leary DH; Grobbee DE; Crouse JR;
    J Intern Med; 2009 Jun; 265(6):698-707. PubMed ID: 19298496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaemia is associated with monocyte activation in HIV-infected adults on antiretroviral therapy.
    Lipshultz HM; Hileman CO; Ahuja S; Funderburg NT; McComsey GA
    Antivir Ther; 2015; 20(5):521-7. PubMed ID: 25668820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of 2-year treatment with low-dose rosuvastatin on intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease.
    Riccioni G; Cipollone F; Santovito D; Scotti L; D'Orazio N; Mezzetti A; Bucciarelli T
    Expert Opin Pharmacother; 2011 Dec; 12(17):2599-604. PubMed ID: 21999752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-classical monocytes predict progression of carotid artery bifurcation intima-media thickness in HIV-infected individuals on stable antiretroviral therapy.
    Chow DC; Kagihara JM; Zhang G; Souza SA; Hodis HN; Li Y; Mitchell BI; Nakamoto BK; Kallianpur KJ; Keating SM; Norris PJ; Kohorn LB; Ndhlovu LC; Shikuma CM
    HIV Clin Trials; 2016 May; 17(3):114-22. PubMed ID: 27125366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study.
    Crouse JR; Bots ML; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Raichlen JS;
    Eur J Cardiovasc Prev Rehabil; 2010 Apr; 17(2):223-9. PubMed ID: 20038840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation.
    Parra S; Coll B; Aragonés G; Marsillach J; Beltrán R; Rull A; Joven J; Alonso-Villaverde C; Camps J
    HIV Med; 2010 Apr; 11(4):225-31. PubMed ID: 19845792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease.
    Morris A; Fitzpatrick M; Bertolet M; Qin S; Kingsley L; Leo N; Kessinger C; Michael H; Mcmahon D; Weinman R; Stone S; Leader JK; Kleerup E; Huang L; Wisniewski SR
    AIDS; 2017 Feb; 31(4):539-544. PubMed ID: 27941393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.
    Moutzouri E; Liberopoulos EN; Tellis CC; Milionis HJ; Tselepis AD; Elisaf MS
    Atherosclerosis; 2013 Nov; 231(1):8-14. PubMed ID: 24125402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy.
    Erlandson KM; Jiang Y; Debanne SM; McComsey GA
    AIDS Res Hum Retroviruses; 2016 Apr; 32(4):311-6. PubMed ID: 26477698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.
    Saeedi R; Johns K; Frohlich J; Bennett MT; Bondy G
    Lipids Health Dis; 2015 Jun; 14():57. PubMed ID: 26087958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated atherosclerosis-related gene expression, monocyte activation and microparticle-release are related to increased lipoprotein-associated oxidative stress in familial hypercholesterolemia.
    Hjuler Nielsen M; Irvine H; Vedel S; Raungaard B; Beck-Nielsen H; Handberg A
    PLoS One; 2015; 10(4):e0121516. PubMed ID: 25875611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy.
    Erlandson KM; Jiang Y; Debanne SM; McComsey GA
    Clin Infect Dis; 2015 Nov; 61(10):1566-72. PubMed ID: 26157049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial.
    Tam LS; Li EK; Shang Q; Tomlinson B; Lee VW; Lee KK; Li M; Kuan WP; Li TK; Tseung L; Yip GW; Freedman B; Yu CM
    Scand J Rheumatol; 2011 Nov; 40(6):411-21. PubMed ID: 21867445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxidized low-density lipoproteins and their antibodies: relationships with the reverse cholesterol transport and carotid atherosclerosis in adults without cardiovascular diseases.
    Ferreira PF; Zago VH; D'Alexandri FL; Panzoldo NB; Gidlund MA; Nakamura RT; Schreiber R; Parra ES; Santiago FD; Nakandakare ER; Quintão EC; de Faria EC
    Clin Chim Acta; 2012 Oct; 413(19-20):1472-8. PubMed ID: 22659061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins to improve cardiovascular outcomes in treated HIV infection.
    Longenecker CT; Eckard AR; McComsey GA
    Curr Opin Infect Dis; 2016 Feb; 29(1):1-9. PubMed ID: 26658651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of oral rosuvastatin intervention on HDL and its associated proteins in men with type 2 diabetes mellitus.
    Naresh S; Bitla AR; Rao PVLNS; Sachan A; Amancharla YL
    Endocrine; 2021 Jan; 71(1):76-86. PubMed ID: 32895874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection.
    El Kamari V; Hileman CO; Gholam PM; Kulkarni M; Funderburg N; McComsey GA
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):536-542.e1. PubMed ID: 29908359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial.
    Trevillyan JM; Dart A; Paul E; Cavassini M; Fehr J; Staehelin C; Dewar EM; Hoy JF; Calmy A
    AIDS; 2021 Mar; 35(4):619-624. PubMed ID: 33252480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.